Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Profit After Tax (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Profit After Tax for 11 consecutive years, with -$107.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax changed N/A to -$107.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$153.9 million, a N/A change, with the full-year FY2025 number at -$153.9 million, down 306.29% from a year prior.
  • Profit After Tax was -$107.1 million for Q4 2025 at Crescent Biopharma, down from -$21.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$8.3 million in Q2 2023 to a low of -$107.1 million in Q4 2025.
  • A 5-year average of -$17.9 million and a median of -$12.0 million in 2022 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: soared 50.82% in 2022, then tumbled 115.84% in 2025.
  • Crescent Biopharma's Profit After Tax stood at -$17.4 million in 2021, then surged by 41.2% to -$10.2 million in 2022, then grew by 11.38% to -$9.1 million in 2023, then fell by 8.21% to -$9.8 million in 2024, then tumbled by 990.53% to -$107.1 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Profit After Tax are -$107.1 million (Q4 2025), -$21.8 million (Q2 2025), and -$15.1 million (Q1 2025).